Suggested remit: To appraise the clinical and cost effectiveness of benralizumab within its marketing authorisation for previously treated severe nasal polyps.
As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of Benralizumab with mometasone furoate for treating severe nasal polyps. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
- Status:
- Suspended
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1659
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 01 April 2025 | Suspended. As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of Benralizumab with mometasone furoate for treating severe nasal polyps. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 05 August 2024 | Note - Note added to the project documents |
| 16 March 2021 | Note added to the project documents |
For further information on our processes and methods, please see our CHTE processes and methods manual